Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15703179 | 0.83 | HMGCR (0.38) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL7806975 | 0.75 | TDP1 (0.47) | TSHRFFAR1CPT2TDP1ALDH1A1 | |
| SCHEMBL12515879 | 0.75 | HMGCR (0.34) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL24754736 | 0.75 | HMGCR (0.46) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL3654996 | 0.75 | HMGCR (0.46) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL11296882 | 0.74 | — | — | |
| SCHEMBL7605166 | 0.73 | HMGCR (0.50) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL30686973 | 0.72 | HMGCR (0.42) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL5634001 | 0.72 | HMGCR (0.42) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL18741280 | 0.71 | HMGCR (0.42) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2527340-B1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-08-17 | — | — | EP | disclosed |
| EP-2407466-B1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| EP-2615084-B1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-9181183-B2 | Prostaglandin D synthase inhibitory piperidine compounds | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-9062035-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-8865714-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-8765750-B2 | Piperazine compound having a PGDS inhibitory effect | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-05-08 | — | — | US | disclosed |
| US-8536141-B2 | Polyacetylenic compounds for protecting against pancreatic islet atrophy | ACADEMIA SINICA (TW) | 2013-09-17 | — | — | US | disclosed |
| EP-2615084-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165438-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20120309760-A1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-2407466-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319413-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110269702-A1 | POLYACETYLENIC COMPOUNDS FOR PROTECTING AGAINST PANCREATIC ISLET ATROPHY | ACADEMIA SINICA (TW) | 2011-11-03 | — | — | US | disclosed |
| EP-1911755-B1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7951956-B2 | Benzoimidazole compound capable of inhibiting prostaglandin D synthetase | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090281098-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1911755-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-4861594-A | EXTRACTION WITH DISTILLED WATER, THIN-LAYER CHROMATOGRAPHY, ELUTION WITH ETHANOL, CENTRIFUGING | UNIVERSITY OF CINCINNATI (US) | 1989-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269702-A1 | POLYACETYLENIC COMPOUNDS FOR PROTECTING AGAINST PANCREATIC ISLET ATROPHY | IAPP, AMY2A, GPR119 | HMGCR 162/4885CHRM1 915/4885TBXA2R 4019/4885 |
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | PTGDR, PTGS1, PTGDR2 | HMGCR 2952/4885CHRM1 872/4885TBXA2R 29/4885 |
| US-20120309760-A1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | GRIK5, GRK5, KCNJ5 | HMGCR 4376/4885CHRM1 301/4885TBXA2R 698/4885 |
| US-20090281098-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | PTGS1, PTGIS, PTGES | HMGCR 2701/4885CHRM1 841/4885TBXA2R 42/4885 |
| US-20130165438-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | PTGIS, PTGS1, PTGDR | HMGCR 4526/4885CHRM1 2202/4885TBXA2R 36/4885 |
| US-20110319413-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | PTGS1, PTGDR, PTGIS | HMGCR 3137/4885CHRM1 732/4885TBXA2R 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.